Two major players in artificial intelligence are putting their money where their mouth is: they're now actively developing drugs themselves. Anthropic, the AI company behind the popular Claude chatbot, announced this week it will begin developing pharmaceutical candidates, while Ohio State University launched a new AI-enabled center designed to accelerate drug discovery and commercialization across central Ohio. The moves signal a critical shift in how the pharmaceutical industry views artificial intelligence, moving beyond hype to hands-on experimentation.

Why Are AI Companies Suddenly Becoming Drug Developers?

For Anthropic, the reasoning is straightforward: the company wants real-world experience using its own AI tools to solve actual scientific problems. Eric Kauderer-Abrams, Anthropic's head of life sciences, explained that the company had been asking itself what it should be doing beyond training models and building products. The answer, executives decided, was to get hands-on experience in drug development itself.

"Ohio State intends to be a national force in therapeutic innovation, where producing new medicines every five to 10 years becomes an expected outcome," said Deanna Kroetz, dean and professor at Ohio State's College of Pharmacy.

Deanna Kroetz, Dean and Professor, College of Pharmacy at Ohio State University

At Ohio State, the timing feels equally urgent. The university's new initiative, called Buckeye BioLaunch, is anchored in the belief that artificial intelligence is transforming drug discovery at remarkable speed. The university has invested in Ohio State Genomic Health (OSGH), which provides access to rich clinical and genomic datasets that researchers can use to train AI models. Combined with the College of Pharmacy's expertise in drug development and the College of Medicine's strengths in clinical research, Ohio State believes it has the ingredients to become a national leader in AI-driven therapeutics.

What Does Buckeye BioLaunch Actually Plan to Do?

Ohio State's new center represents a coordinated, university-wide effort to move discoveries from the lab toward real-world impact. The initiative involves collaboration across the Ohio State Wexner Medical Center, the Ohio State Comprehensive Cancer Center, and the Colleges of Medicine and Pharmacy. Rather than focusing on a single drug or disease, Buckeye BioLaunch will support projects across the full continuum of drug development.

• Screening Projects: The center aims to support between 10 to 20 AI-driven screening projects annually, creating a robust pipeline of therapeutic candidates advancing toward commercialization.
• Development Stages: Projects will span from genomics to target identification to molecule design to final medicine development, covering the entire drug discovery journey.
• Success Metrics: Progress will be measured through new composition-of-matter patents, technical development milestones, licenses, startup formation, and clinical trials launched.

The strategic investment complements several other new initiatives at Ohio State, including new faculty hires in computational chemistry, genomics, and health data artificial intelligence through the university's AI Faculty Hiring Initiative. Ohio State has also launched the AI(X) Hub, a collaborative research center dedicated to advancing artificial intelligence research and innovation across disciplines including healthcare.

How Does This Fit Into the Broader AI Drug Discovery Landscape?

Both Anthropic and Ohio State are entering a field that has attracted billions in investment from major pharmaceutical companies. However, their approaches differ slightly. Anthropic is using its Claude Science product, a new application launched this week specifically aimed at researchers and the pharmaceutical industry, to begin developing drug candidates internally. The company has emphasized that it is unclear whether Anthropic intends to bring drug candidates all the way through to commercialization, but executives stressed the importance of gaining firsthand experience with their own tools.

Ohio State's approach is more focused on infrastructure and ecosystem building. By creating a centralized hub that brings together clinicians, researchers, and drug development experts, the university is positioning itself as a regional engine for biotech growth. John J. Warner, CEO of Ohio State Wexner Medical Center, noted that the effort aligns with the medical center's commitment to delivering the best care while driving healthcare transformation across Ohio and nationally.

"The 'why now' is simple: AI is transforming drug discovery at a remarkable speed, and the Wexner Medical Center's investment in Ohio State Genomic Health gives us the rich clinical and genomic datasets needed to lead," explained Deanna Kroetz.

Deanna Kroetz, Dean and Professor, College of Pharmacy at Ohio State University

What makes these announcements significant is that they represent a maturation of AI in drug discovery. Rather than relying solely on external partnerships or licensing agreements, both organizations are now betting that direct involvement in drug development will yield competitive advantages. For Anthropic, it's a way to validate Claude's capabilities in a high-stakes domain. For Ohio State, it's a way to leverage its academic research strengths and clinical data to create a sustainable pipeline of new therapeutics for patients in Ohio and beyond.

The success of these initiatives will likely influence how other academic institutions and AI companies approach drug discovery in the coming years. If Buckeye BioLaunch successfully moves multiple candidates toward clinical trials, and if Anthropic demonstrates that its AI tools can meaningfully accelerate drug development, the model could become a blueprint for how universities and technology companies collaborate on pharmaceutical innovation.